Journey Medical (DERM) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Journey Medical (DERM) has outperformed Organigram Global (OGI) over the past year, losing 21.2% versus a loss of 51.0%. Journey Medical is the larger company by market cap ($167.9 million vs $137.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | OGI |
|---|---|---|
| Share price | $5.95 | $0.9511 |
| Market cap | $167.94M | $137.10M |
| 1-day change | 0.00% | -0.93% |
| YTD return | -22.83% | -42.86% |
| 1-year return | -21.19% | -51.02% |
| 5-year return | — | -89.29% |
| P/E ratio (TTM) | — | 2.21 |
| Forward P/E | — | 39.63 |
| EPS (TTM) | $-0.22 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.56 | $2.24 |
| 52-week low | $4.31 | $0.853 |
| Distance from 52-week high | -37.73% | -57.54% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +131.09% | — |
| Average volume | 182.16K | 882.38K |
| Shares outstanding | 22.22M | 144.15M |
| Employees | 58 | 1,139 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DERM has outperformed OGI by 29.8 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
DERM vs OGI FAQ
Which is bigger, Journey Medical or Organigram Global?
Journey Medical (DERM) is larger, with a market capitalization of $167.94M compared with $137.10M for Organigram Global (OGI).
Which stock has performed better over the past year, DERM or OGI?
DERM returned -21.19% over the past 12 months, compared with -51.02% for OGI (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and Organigram Global in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.